GPR40 Agonist Program

About Liminal BioSciences

Liminal BioSciences is a private, pre-revenue biotech company targeting significant unmet needs in metabolic, fibrotic, and inflammatory diseases through a targeted GPCR-focused pipeline. Its core strategy leverages a proprietary discovery platform to develop selective small molecule antagonists and agonists, with three disclosed preclinical/early-stage programs. The company faces the typical high-risk, high-reward profile of early-stage drug development but is positioned in large and growing therapeutic markets with substantial medical need.

Therapeutic Areas

Other Type 2 Diabetes / Metabolic Disease Drugs